Daiichi Sankyo Co., Ltd.
Clinical trials sponsored by Daiichi Sankyo Co., Ltd., explained in plain language.
-
New drug hope for rare joint tumor patients who Can't have surgery
Disease control CompletedThis study tested a drug called pexidartinib (TURALIO) in 9 Japanese adults with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous growth in the joints that causes pain and limits movement. The goal was to see if the drug is safe and can shrink tumors in people whose tu…
Phase: PHASE2 • Sponsor: Daiichi Sankyo Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Experimental drug shows promise for rare melanoma type
Disease control CompletedThis early-stage study tested an experimental drug called PLX3397 in 6 people with advanced melanoma that has a specific KIT gene mutation and cannot be removed by surgery. The goal was to check the drug's safety and see if it could shrink tumors. While some patients had their tu…
Phase: NA • Sponsor: Daiichi Sankyo Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC